Tag: Prescription Drugs
Continuing Tirzepatide Leads to Maintenance of Weight Reduction
Continued tirzepatide treatment maintains and augments initial weight reduction seen in first 36 weeks
Risk for CRC Reduced With GLP-1RAs for Drug-Naive Patients With T2D
GLP-1 receptor agonists linked to reduced risk for CRC compared with other antidiabetics, including insulin and metformin
Mirvetuximab Soravtansine-Gynx Beneficial for FRα-Positive Ovarian Cancer
Longer progression-free survival seen, and significantly more patients had objective response than those receiving chemo
Daily Baricitinib Treatment Preserves β-Cell Function in Type 1 Diabetes
Mixed-meal-stimulated mean C-peptide levels at 48 weeks higher for those treated with baricitinib versus placebo
Slow-to-Moderate Weight Loss Linked to Lower Mortality in Knee, Hip OA
Weight loss has dose-response protective effect on incident hypertension, type 2 diabetes, venous thromboembolism
White House Looks to Curb Big Pharma’s Sky-High Drug Prices
If a drug is too expensive, the Biden administration will use federal law to grant patent licenses to rival pharma companies
Eli Lilly Says Its New Weight-Loss Drug, Zepbound, Is Now Available
Tirzepatide, the active ingredient in Zepbound, had already been approved by the FDA as a treatment for type 2 diabetes
CVD Mortality Similar With Diuretic, ACE Inhibitor, or Calcium Channel Blocker
Those randomly assigned to receive ACE inhibitor had increased risks for stroke mortality, fatal and nonfatal hospitalized stroke versus diuretic group
Psychostimulants Beneficial for Amphetamine-Type Stimulant Use Disorder
Higher doses of prescription psychostimulants, treatment duration positively linked to longer retention
Four JAK Inhibitors Have Comparable Efficacy, Safety for RA
Baseline CRP, Clinical Disease Activity Index, glucocorticoid dose predict resistance to CDAI-low disease activity achievement
